Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Repro Med Systems...

    Repro Med Systems issued a warning by the FDA

    Written by savita thakur thakur Published On 2016-03-11T12:38:04+05:30  |  Updated On 11 March 2016 12:38 PM IST
    Repro Med Systems issued a warning by the  FDA
    New York: Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR), a leading developer and manufacturer of medical devices and supplies, announced that on February 26, 2016, RMS Medical Products, Inc. (“RMS”) received a Warning Letter (WL NYK-2016-26) from the New York District Office of US Food and Drug Administration (“FDA”) based on the observations of an FDA inspection which occurred in June 2015.

    During the audit, the FDA identified several areas of improvement; many of those items have been completed to the agency’s satisfaction. There are three items that require additional clarification and RMS Medical Products is in the process of addressing these issues and providing the additional documentation needed.

    There were no safety concerns raised by the points made in the warning letter.

    “While we anticipate one item taking a bit longer to resolve, the others are merely an exercise in better communicating our thorough processes and premium safety standards to the FDA,” said Dr. Fred Ma, Chief Medical Officer at RMS Medical Products. “As always, we remain committed to uncompromised safety and quality for all of our products.”

    Dr. Ma and RMS Medical Products’ management are working in collaboration with external FDA consultants and investigators to remediate all matters as efficaciously as possible. While the three items are being addressed, the company will continue to operate in full compliance with all ISO 13485 and FDA QSR regulatory requirements (i.e. 21CFR Part 820) applicable to their products.

    The company is directing all inquiries to Corinne Colaianni at 845.469.2042.



    Dr. Fred MaOTCQX: REPRRepro MedRMS Medical ProductsUS Food and Drug AdministrationUSFDAWL NYK-2016-26

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok